Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, USA.
J Neuroophthalmol. 2010 Jun;30(2):117-22. doi: 10.1097/WNO.0b013e3181d8e4af.
A 52-year-old man with chronic hepatitis C presented with painless, bilateral, simultaneous nonarteritic anterior ischemic optic neuropathy (NAION) and peripheral neuropathy. Symptoms began 19 weeks after starting peginterferon alpha-2a. The peripheral neuropathy and vision of the right eye improved, but the vision of the left eye worsened after stopping interferon. We identified 23 additional cases of NAION during interferon alpha therapy. At least 12 of these patients suffered bilateral NAION. Patients lost vision 1-40 weeks after initiating therapy. Of 21 eyes that had documented initial and follow-up acuities, 8 improved, 1 worsened, and the rest remained stable. One patient had a painful peripheral neuropathy. Treatment with interferon alpha may result in NAION. Discontinuation of therapy deserves consideration after weighing individual risks and benefits.
一位 52 岁男性患有慢性丙型肝炎,出现无痛性双侧同时性前部缺血性视神经病变(NAION)和周围神经病。症状在开始使用聚乙二醇干扰素α-2a 19 周后出现。停止干扰素后,右侧眼的周围神经病和视力有所改善,但左眼视力恶化。我们在干扰素α治疗期间发现了另外 23 例 NAION。这些患者中至少有 12 例患有双侧 NAION。患者在开始治疗后 1-40 周内失去视力。在有记录初始和随访视力的 21 只眼中,8 只眼视力改善,1 只眼视力恶化,其余保持稳定。1 例患者出现疼痛性周围神经病。使用干扰素α治疗可能导致 NAION。在权衡个人风险和收益后,应考虑停止治疗。